ARTICLE | Strategy
De-risking risk reduction
What Illumina hopes to accomplish with the first-ever value-based diagnostics deal
March 2, 2018 10:58 PM UTC
Slow and inconsistent reimbursement practices coupled with a lack of data on health or economic outcomes at launch often slows uptake of new, high-priced molecular diagnostics and sequencing-based tests.
A first-of-its kind deal between Illumina Inc. and Harvard Pilgrim Health Care Inc. is intended to generate data to support broad reimbursement by multiple payers for non-invasive prenatal tests made by multiple testing companies...